56809-84-8

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Dichloro-5-nitropyridine is used as a key intermediate for the synthesis of various active pharmaceutical ingredients. Its unique structure and reactivity allow for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3,4-Dichloro-5-nitropyridine is employed as a building block in the creation of compounds with pesticidal or herbicidal activity, contributing to the development of effective crop protection agents.
Used in Organic Chemistry Research:
3,4-Dichloro-5-nitropyridine is utilized as a versatile intermediate in organic chemistry research for the exploration of novel reactions and the synthesis of complex organic molecules, further expanding the scope of chemical applications.

InChI:InChI=1/C5H2Cl2N2O2/c6-3-1-8-2-4(5(3)7)9(10)11/h1-2H

Upstream product

• 5435-54-1 4-hydroxy-3-nitropyridine 
• 31872-64-7 3-chloro-4-hydroxy-5-nitropyridine 

Downstream Products

• 1186084-29-6 4-chloro-N-({1-[(3S)-3-methylpiperazin-1-yl]cyclohexyl}methyl)-1-pyrimidin-2-yl-1H-pyrrolo[2,3-c]pyridine-3-carboxamide 

Relevant academic research and scientific papers

4 - SUBSTITUTED 1, 3 - DIHYDRO - 2H - BENZIMIDAZOL - 2 - ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS

The present invention is concerned with novel 4-substituted 1,3-dihydro-2H- benzimidazol-2-one derivatives substituted with benzimidazoles having formula (I), tautomers and stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof, wherein R4, R5, Z and Het have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.

1,3 -DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS

The present invention is concerned with novel 4-substituted 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles having formula (I) tautomers and stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof, wherein R4, R5, Z and Het have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.

HETEROARYL AMIDE ANALOGUES

Compounds, pharmaceutical compositions, and methods of use are disclosed for heteroaryl amide analogues of formula Ia and/or Ib. In certain embodiments, the heteroaryl amide analogues are agonists and/or ligands of dopamine receptors and may be useful, inter alia, for the treatment of a condition responsive to P2X7 receptor modulation, for example, pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system disorder.

7′-Substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors

We report on the discovery of benzo- and pyridinothiazolothiopurines as potent heat shock protein 90 inhibitors. The benzothiazole moiety is exceptionally sensitive to substitutions on the aromatic ring with a 7′-substituent essential for activity. Some of these compounds exhibit low nanomolar inhibition activity in a Her-2 degradation assay (28-150 nM), good aqueous solubility, and oral bioavailability profiles in mice. In vivo efficacy experiments demonstrate that compounds of this class inhibit tumor growth in an N87 human colon cancer xenograft model via oral administration as shown with compound 37 (8-(7-chloro-benzothiazol-2-ylsulfanyl)-9-(2-cyclopropylamino-ethyl) -9H-purin-6-ylamine).